# Lifevantage Corp: financial statements, quarterly

LFVN · Nasdaq · CIK 849146 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lfvn.md) · [Financials](/companies/lfvn/financials.md) · [Filings](/companies/lfvn/filings.md) · [Insiders](/companies/lfvn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lfvn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [51.4](/filings/0000849146-24-000121.md) | [51.6](/filings/0000849146-25-000014.md) | [48.2](/filings/0000849146-25-000039.md) | [48.9 d](/filings/0000849146-25-000068.md) | [47.2](/filings/0001628280-25-048792.md) | [67.8](/filings/0001628280-26-005428.md) | [58.4](/filings/0001193125-26-208922.md) | [55.1 d](/filings/0001193125-26-371257.md) | [47.6](/filings/0001628280-25-048792.md) | [48.9](/filings/0001628280-26-005428.md) | [43.7](/filings/0001193125-26-208922.md) | [42.4 d](/filings/0001193125-26-371257.md) |
| Cost of revenue | $m | [10.2](/filings/0000849146-24-000121.md) | [11.1](/filings/0000849146-25-000014.md) | [10.2](/filings/0000849146-25-000039.md) | [10.0 d](/filings/0000849146-25-000068.md) | [9.5](/filings/0001628280-25-048792.md) | [13.2](/filings/0001628280-26-005428.md) | [11.1](/filings/0001193125-26-208922.md) | [11.1 d](/filings/0001193125-26-371257.md) | [9.7](/filings/0001628280-25-048792.md) | [12.7](/filings/0001628280-26-005428.md) | [9.2](/filings/0001193125-26-208922.md) | [9.3 d](/filings/0001193125-26-371257.md) |
| Gross profit | $m | [41.2](/filings/0000849146-24-000121.md) | [40.6](/filings/0000849146-25-000014.md) | [38.1](/filings/0000849146-25-000039.md) | [38.9 d](/filings/0000849146-25-000068.md) | [37.7](/filings/0001628280-25-048792.md) | [54.6](/filings/0001628280-26-005428.md) | [47.3](/filings/0001193125-26-208922.md) | [44.0 d](/filings/0001193125-26-371257.md) | [37.8](/filings/0001628280-25-048792.md) | [36.2](/filings/0001628280-26-005428.md) | [34.5](/filings/0001193125-26-208922.md) | [33.0 d](/filings/0001193125-26-371257.md) |
| Research and development | $m | [0.2](/filings/0000849146-24-000121.md) | [0.1](/filings/0000849146-25-000014.md) | [0.2](/filings/0000849146-25-000039.md) | [0.2 d](/filings/0000849146-25-000068.md) | [0.3](/filings/0001628280-25-048792.md) | [0.2](/filings/0001628280-26-005428.md) | [0.4](/filings/0001193125-26-208922.md) | [0.4 d](/filings/0001193125-26-371257.md) | [0.3](/filings/0001628280-25-048792.md) | [0.2](/filings/0001628280-26-005428.md) | [0.2](/filings/0001193125-26-208922.md) | [0.2 d](/filings/0001193125-26-371257.md) |
| Selling, general and administrative | $m | [18.0](/filings/0000849146-24-000121.md) | [20.1](/filings/0000849146-25-000014.md) | [16.4](/filings/0000849146-25-000039.md) | [14.0 d](/filings/0000849146-25-000068.md) | [14.8](/filings/0001628280-25-048792.md) | [18.6](/filings/0001628280-26-005428.md) | [17.1](/filings/0001193125-26-208922.md) | [18.7 d](/filings/0001193125-26-371257.md) | [14.9](/filings/0001628280-25-048792.md) | [15.8](/filings/0001628280-26-005428.md) | [13.9](/filings/0001193125-26-208922.md) | [13.9 d](/filings/0001193125-26-371257.md) |
| Operating income | $m | [0.7](/filings/0000849146-24-000121.md) | [(1.3)](/filings/0000849146-25-000014.md) | [1.9](/filings/0000849146-25-000039.md) | [2.9 d](/filings/0000849146-25-000068.md) | [2.6](/filings/0001628280-25-048792.md) | [3.4](/filings/0001628280-26-005428.md) | [4.1](/filings/0001193125-26-208922.md) | [2.1 d](/filings/0001193125-26-371257.md) | [2.3](/filings/0001628280-25-048792.md) | [0.5](/filings/0001628280-26-005428.md) | [1.7](/filings/0001193125-26-208922.md) | [1.7 d](/filings/0001193125-26-371257.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.2](/filings/0000849146-24-000121.md) | [(0.5)](/filings/0000849146-25-000014.md) | [0.3](/filings/0000849146-25-000039.md) | [1.4 d](/filings/0000849146-25-000068.md) | [0.8](/filings/0001628280-25-048792.md) | [0.5](/filings/0001628280-26-005428.md) | [0.7](/filings/0001193125-26-208922.md) | [0.4 d](/filings/0001193125-26-371257.md) | [0.1](/filings/0001628280-25-048792.md) | [0.2](/filings/0001628280-26-005428.md) | [0.3](/filings/0001193125-26-208922.md) | [0.4 d](/filings/0001193125-26-371257.md) |
| Net income | $m | [0.6](/filings/0000849146-25-000039.md) | [(0.7)](/filings/0000849146-25-000039.md) | [1.7](/filings/0000849146-25-000039.md) | [1.3 d](/filings/0000849146-25-000068.md) | [1.8](/filings/0001193125-26-208922.md) | [2.6](/filings/0001193125-26-208922.md) | [3.5](/filings/0001193125-26-208922.md) | [2.0 d](/filings/0001193125-26-371257.md) | [2.2](/filings/0001193125-26-208922.md) | [0.3](/filings/0001193125-26-208922.md) | [1.4](/filings/0001193125-26-208922.md) | [1.3 d](/filings/0001193125-26-371257.md) |
| Diluted EPS | $ per share | [0.05](/filings/0000849146-24-000121.md) | [(0.05)](/filings/0000849146-25-000014.md) | [0.13](/filings/0000849146-25-000039.md) | not reported | [0.14](/filings/0001628280-25-048792.md) | [0.19](/filings/0001628280-26-005428.md) | [0.26](/filings/0001193125-26-208922.md) | not reported | [0.17](/filings/0001628280-25-048792.md) | [0.02](/filings/0001628280-26-005428.md) | [0.11](/filings/0001193125-26-208922.md) | not reported |
| Basic EPS | $ per share | [0.05](/filings/0000849146-24-000121.md) | [(0.05)](/filings/0000849146-25-000014.md) | [0.13](/filings/0000849146-25-000039.md) | not reported | [0.15](/filings/0001628280-25-048792.md) | [0.21](/filings/0001628280-26-005428.md) | [0.28](/filings/0001193125-26-208922.md) | not reported | [0.17](/filings/0001628280-25-048792.md) | [0.02](/filings/0001628280-26-005428.md) | [0.11](/filings/0001193125-26-208922.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [16.9](/filings/0000849146-25-000068.md) | not reported | not reported | not reported | [20.2](/filings/0000849146-25-000068.md) | not reported | not reported | not reported | not reported |
| Current assets | $m | [41.9](/filings/0000849146-23-000204.md) | [38.7](/filings/0000849146-24-000016.md) | [37.8](/filings/0000849146-24-000047.md) | [37.6](/filings/0000849146-25-000068.md) | [38.8](/filings/0000849146-24-000121.md) | [45.8](/filings/0000849146-25-000014.md) | [54.1](/filings/0000849146-25-000039.md) | [50.9](/filings/0001193125-26-371257.md) | [45.0](/filings/0001628280-25-048792.md) | [38.6](/filings/0001628280-26-005428.md) | [39.3](/filings/0001193125-26-208922.md) | [38.3](/filings/0001193125-26-371257.md) |
| Total assets | $m | [66.6](/filings/0000849146-23-000204.md) | [62.7](/filings/0000849146-24-000016.md) | [61.3](/filings/0000849146-24-000047.md) | [60.3](/filings/0000849146-25-000068.md) | [61.5](/filings/0000849146-24-000121.md) | [68.5](/filings/0000849146-25-000014.md) | [77.2](/filings/0000849146-25-000039.md) | [72.0](/filings/0001193125-26-371257.md) | [61.6](/filings/0001628280-25-048792.md) | [61.2](/filings/0001628280-26-005428.md) | [62.1](/filings/0001193125-26-208922.md) | [62.1](/filings/0001193125-26-371257.md) |
| Current liabilities | $m | [24.7](/filings/0000849146-23-000204.md) | [23.0](/filings/0000849146-24-000016.md) | [22.5](/filings/0000849146-24-000047.md) | [22.3](/filings/0000849146-25-000068.md) | [22.1](/filings/0000849146-24-000121.md) | [27.5](/filings/0000849146-25-000014.md) | [32.6](/filings/0000849146-25-000039.md) | [27.2](/filings/0001193125-26-371257.md) | [18.8](/filings/0001628280-25-048792.md) | [19.0](/filings/0001628280-26-005428.md) | [20.1](/filings/0001193125-26-208922.md) | [20.2](/filings/0001193125-26-371257.md) |
| Total liabilities | $m | [37.3](/filings/0000849146-23-000204.md) | [35.4](/filings/0000849146-24-000016.md) | [34.5](/filings/0000849146-24-000047.md) | [34.3](/filings/0000849146-25-000068.md) | [33.8](/filings/0000849146-24-000121.md) | [38.6](/filings/0000849146-25-000014.md) | [43.2](/filings/0000849146-25-000039.md) | [37.3](/filings/0001193125-26-371257.md) | [28.4](/filings/0001628280-25-048792.md) | [28.2](/filings/0001628280-26-005428.md) | [28.8](/filings/0001193125-26-208922.md) | [28.5](/filings/0001193125-26-371257.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [29.3](/filings/0000849146-25-000039.md) | [27.3](/filings/0000849146-25-000039.md) | [26.8](/filings/0000849146-25-000039.md) | [26.0](/filings/0001193125-26-371257.md) | [27.7](/filings/0001193125-26-208922.md) | [29.9](/filings/0001193125-26-208922.md) | [34.0](/filings/0001193125-26-208922.md) | [34.6](/filings/0001193125-26-371257.md) | [33.2](/filings/0001193125-26-208922.md) | [33.0](/filings/0001193125-26-208922.md) | [33.3](/filings/0001193125-26-208922.md) | [33.6](/filings/0001193125-26-371257.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [4,765](/filings/0000849146-24-000121.md) | [1,757 d](/filings/0000849146-25-000014.md) | [3,093 d](/filings/0000849146-25-000039.md) | [2,582 d](/filings/0000849146-25-000068.md) | [(583)](/filings/0001628280-25-048792.md) | [9,199 d](/filings/0001628280-26-005428.md) | [2,228 d](/filings/0001193125-26-208922.md) | [1,034 d](/filings/0001193125-26-371257.md) | [(2,305)](/filings/0001628280-25-048792.md) | [2,791 d](/filings/0001628280-26-005428.md) | [4,988 d](/filings/0001193125-26-208922.md) | [4,767 d](/filings/0001193125-26-371257.md) |
| Capital expenditure | $k | [1,133](/filings/0000849146-24-000121.md) | [543 d](/filings/0000849146-25-000014.md) | [291 d](/filings/0000849146-25-000039.md) | [278 d](/filings/0000849146-25-000068.md) | [349](/filings/0001628280-25-048792.md) | [492 d](/filings/0001628280-26-005428.md) | [331 d](/filings/0001193125-26-208922.md) | [199 d](/filings/0001193125-26-371257.md) | [439](/filings/0001628280-25-048792.md) | [1,084 d](/filings/0001628280-26-005428.md) | [1,011 d](/filings/0001193125-26-208922.md) | [1,037 d](/filings/0001193125-26-371257.md) |
| Dividends paid | $k | [5,534](/filings/0000849146-24-000121.md) | [455 d](/filings/0000849146-25-000014.md) | [448 d](/filings/0000849146-25-000039.md) | [503 d](/filings/0000849146-25-000068.md) | [500](/filings/0001628280-25-048792.md) | [502 d](/filings/0001628280-26-005428.md) | [503 d](/filings/0001193125-26-208922.md) | [562 d](/filings/0001193125-26-371257.md) | [571](/filings/0001628280-25-048792.md) | [575 d](/filings/0001628280-26-005428.md) | [573 d](/filings/0001193125-26-208922.md) | [625 d](/filings/0001193125-26-371257.md) |
| Share repurchases | $k | [795](/filings/0000849146-24-000121.md) | [1,900](/filings/0000849146-25-000014.md) | [1,900](/filings/0000849146-25-000039.md) | [1,831 d](/filings/0000849146-25-000068.md) | [1,114](/filings/0001628280-25-048792.md) | [0.0](/filings/0000849146-25-000014.md) | [0.0](/filings/0000849146-25-000039.md) | [2,033 d](/filings/0001193125-26-371257.md) | [578](/filings/0001628280-25-048792.md) | [(1.0) d](/filings/0001628280-26-005428.md) | [1,006 d](/filings/0001193125-26-208922.md) | [460 d](/filings/0001193125-26-371257.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.5](/filings/0000849146-23-000204.md) | [12.5](/filings/0000849146-24-000016.md) | [12.8](/filings/0000849146-24-000047.md) | [13.1](/filings/0000849146-24-000121.md) | [12.6](/filings/0000849146-25-000014.md) | [13.0](/filings/0000849146-25-000039.md) | [12.8](/filings/0001628280-25-048792.md) | [13.2](/filings/0001628280-26-005428.md) | [13.3](/filings/0001193125-26-208922.md) | [12.9](/filings/0001628280-25-048792.md) | [12.7](/filings/0001628280-26-005428.md) | [12.7](/filings/0001193125-26-208922.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,527,348 at 2026-08-26, from the cover of the [10-K filed 2026-08-27](/filings/0001193125-26-371257.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.